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Facioscapulohumeral muscular dystrophy (FSHD) is a common hereditary myopathy causally linked to reduced numbers (%8) of 3.3
kilobase D4Z4 tandem repeats at 4q35. However, because individuals carrying D4Z4-reduced alleles and no FSHD and patients with
FSHD and no short allele have been observed, additionalmarkers have been proposed to support an FSHDmolecular diagnosis. In partic-
ular a reduction in the number of D4Z4 elements combined with the 4A(159/161/168)PAS haplotype (which provides the possibility of
expressing DUX4) is currently used as the genetic signature uniquely associated with FSHD. Here, we analyzed these DNA elements in
more than 800 Italian and Brazilian samples of normal individuals unrelated to any FSHD patients. We find that 3% of healthy subjects
carry alleles with a reduced number (4–8) of D4Z4 repeats on chromosome 4q and that one-third of these alleles, 1.3%, occur in combi-
nation with the 4A161PAS haplotype. We also systematically characterized the 4q35 haplotype in 253 unrelated FSHD patients. We find
that only 127 of them (50.1%) carry alleles with 1–8 D4Z4 repeats associated with 4A161PAS, whereas the remaining FSHD probands
carry different haplotypes or alleles with a greater number of D4Z4 repeats. The present study shows that the current genetic signature
of FSHD is a common polymorphism and that only half of FSHD probands carry this molecular signature. Our results suggest that
the genetic basis of FSHD, which is remarkably heterogeneous, should be revisited, because this has important implications for genetic
counseling and prenatal diagnosis of at-risk families.Introduction
Facioscapulohumeral muscular dystrophy (FSHD [MIM
158900]), a common myopathy, has a prevalence of 1 in
20,000.1,2 The disease is characterized byweakness of selec-
tive muscle groups and wide variability of clinical expres-
sion.1,3,4 The onset of the disease is in the second or third
decade of life and usually involves the weakening of facial
and limb-girdle muscles. The mode of inheritance of
classical FSHD is considered to be autosomal dominant,
with complete penetrance by age 20.4,5 No biochemical,
histological, or instrumental markers are available to inde-
pendently confirm a specific FSHD diagnosis that remains
mainly clinical.
The FSHD genetic defect does not reside in any protein-
coding gene.6 Instead, FSHD has been genetically linked
to the reduction of an integral number of tandem 3.3-kb1Department of Biomedical Sciences, University of Modena and Reggio Emilia
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nearly identical D4Z4 sequences reside on chromosome
10q26,9 only subjects with a reduced number of D4Z4
repeats on chromosome 4, but not chromosome 10,
develop FSHD.10–12 Based on these results, p13E-11 EcoRI
alleles larger than 50 kb (R11 D4Z4 repeats) originating
from chromosome 4 have been considered normal,
whereas alleles of 35 kb or less (%8 D4Z4 repeats) have
been considered diagnostic for the disease.8,13
Because there are individuals with reduced D4Z4 alleles
that do not have clinical signs of FSHD,14,15 it has been pro-
posed that additional DNA sequences flanking the D4Z4
repeat array are necessary for disease development.16–18
These studies concluded that D4Z4 reduction is pathogenic
only in a few genetic backgrounds, which include a specific
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Figure 1. Schematic Representation of Polymorphisms at the 4q and 10q Subtelomeres
(A) Schematic representation of the method used to calculate D4Z4 repeat numbers from EcoRI fragment sizes. The D4Z4 repeat array is
indicated with triangles. Seven and eight D4Z4 repeats (31–36 kb EcoRI fragment size) were defined to be the upper diagnostic range for
FSHD. D4Z4 repeat units on chromosomes 4 and 10 can be distinguished because all repeats on 10q contain BlnI restriction sites
(B within the black triangles), whereas all D4Z4 repeats on 4q contain XapI restriction sites (X within the white triangles).
(B) Schematic representation of the current view of pathogenic haplotypes.
(C) Elements examined in the present study. In addition to the number of D4Z4 repeats, elements that distinguish subjects include: (1)
the chromosomal localization of the D4Z4 repeat, chromosome 4q35 or 10q26; (2) the SSLP, which is a combination of five variable
number tandem repeats, an 8 bp insertion/deletion, and two SNPs localized 3.5 kb proximal to D4Z4; it varies in length between 157
and 182 bp; (3) the AT(T/C)AAA SNP in the pLAM region; (4) a large sequence variation (termed 4qA or B) that is distal to D4Z4. In
the 4qB variant, the terminal 3.3 kb repeat contains only 570 bp of a complete repeat, whereas in the 4qA variant the terminal repeat
is a divergent 3.3 kb repeat named pLAM. 4q chromosomes that do not hybridize to probes for (A) and (B) are termed ‘‘null,’’ and their
sequences vary from case to case.the repeat (Figure 1). These haplotypes, named 4A159,
4A161, and 4A168, have been proposed to be uniquely
associated with FSHD. Recently it has been shown that
a single-nucleotide polymorphism (SNP) in the pLAM
sequence of the 4qA alleles provides a polyadenylation
signal (PAS; ATTAAA) for the DUX4 transcript from the
most distal D4Z4 unit on 4qA chromosomes. Thus, the
molecular signature, named 4A(159,161,168)PAS, has
been proposed to define alleles causally related to FSHD.
This signature results from the combination of (1) a reduc-
tion in the number of D4Z4 elements, (2) the presence of
the 4qA allele, and (3) the PAS in the pLAM sequence. In
this scenario, FSHD arises from a specific genetic setting
enabling the normally silent double homeobox protein 4
gene (DUX4 [MIM606009]) tobe expressed.18On this basis,
healthy subjects carrying reduced D4Z4 alleles would be
explained by the absence of the 4A(159,161,168)PAS.The AmThis model does not apply to all FSHD cases. For
example, nonpenetrant carriers have been reported in
FSHD families,14,15 and there are FSHD patients carrying
full-length D4Z4 alleles (R11 repeats) that are clinically
indistinguishable from patients carrying D4Z4 alleles of
reduced size (%8 repeats).19 Rare exceptions could be ex-
plained by a variety of mechanisms that do not challenge
the basic hypothesis. However, recently we found that
2.7% of cases in the Italian National Registry for FSHD
(which contains over 1,100 unrelated FSHD patients)
were compound heterozygotes carrying two D4Z4-reduced
alleles (0.5% were homozygotes for the 4A161 haplotype).
Based on this finding, we estimated that the population
frequency of the 4A161PAS haplotype associated with a
D4Z4-reduced allele could be higher than 1%.20
The correlation between genotype and phenotype in
FSHD thus appears to be more complex than just theerican Journal of Human Genetics 90, 628–635, April 6, 2012 629
presence of the 4APAS signature. In order to confirm the
high frequency of this signature in the normal population
and reevaluate the allele distribution in FSHD patients, we
performed a systematic unbiased clinical and molecular
study of 801 normal control subjects from Italy and Brazil
and 253 FSHD probands from the Italian Registry for
FSHD. Our results establish that the 4APAS structure is
a frequent genetic polymorphism that is neither sufficient
nor necessary for the development of FSHD. This result is
not incompatible with evidence implicating DUX4 or
other factors as important mediators of the disease.
However, it does demonstrate that the pathogenesis is
more complex than currently thought and that the current
genetic signature is insufficient for diagnosis.Subjects and Methods
Control Population
The control group consisted of 801 unrelated healthy subjects
with no family history of muscular dystrophy. Subjects were
recruited from the Italian and Brazilian populations through
advertisements. Italian controls subjects were equally distributed
among Northern, Central, and Southern regions. The local ethics
committee approved the study. All subjects enrolled in the
study were clinically and molecularly characterized after giving
informed consent to participate (see Table S1 available online).FSHD Patients
Two-hundred-fifty-three unrelated FSHD patients were accrued
through the Italian National Registry for FSHD. All subjects were
clinically and molecularly characterized. In particular, we consid-
ered patients to have typical FSHD if: (1) disease onset occurred
in facial or shoulder girdle muscles; (2) there was facial and/or
scapular fixator weakness; and (3) there was absence of atypical
signs suggesting an alternative diagnosis (including extraocular,
masticatory, pharyngeal, or lingual muscle weakness and cardio-
myopathy).21,22 Clinical data were collected with the FSHD
clinical form. The clinical severity of the disease was measured
according to the FSHD score, as previously described.23 Briefly,
the FSHD score quantifies the degree of weakness and defines
the level of disability affecting six separate muscle groups: facial
(score 0–2), shoulder girdle (score 0–3), upper limbs (score 0–2),
pelvic girdle (score 0–5), leg muscles (score 0–3), and Beevor’s
sign (score 0–1).23 The final clinical evaluation score, calculated
by summing the single scores, ranged from 0, when no signs of
muscle weakness are present, to 15, when all muscle groups tested
are severely impaired.23 All selected subjects were evaluated using
a standard protocol, and each subject received the standardized
FSHD score previously described.23Molecular Genetic Analysis
DNA was prepared from isolated lymphocytes according to stan-
dard procedures. In brief, restriction endonuclease digestion of
DNA was performed in agarose plugs with the appropriate restric-
tion enzyme: EcoRI, EcoRI/BlnI, XapI (p13E-11 probe), Hind III
(4qA/4qB probes), and NotI (B31 probe). Digested DNA was
separated by pulsed-field gel electrophoresis (PFGE) in 1% agarose
gels. Allele sizes were estimated by southern hybridization with
probe p13E-11 of 7 mg of EcoRI-, EcoRI/BlnI-, and XapI-digested630 The American Journal of Human Genetics 90, 628–635, April 6, 2genomic DNA extracted from peripheral blood lymphocytes,
electrophoresed in a 0.4% agarose gel for 45–48 hr at 35 V, along-
side an 8–48 kb marker (Bio-Rad). To assess the chromosomal
origin of the two D4Z4-reduced alleles, DNA from each proband
was analyzed by NotI digestion and hybridization with the
B31 probe (Figure S1). Restriction fragments were detected
by autoradiography or by using a Typhoon Trio system (GE
Healthcare).
4qA/4qB allelic variants were defined using 7 mg of HindIII-
digested DNA, PFGE electrophoresis, and Southern blot hybridiza-
tion with radiolabeled 4qB and 4qA probes according to standard
procedures. The 4qA/4qB variants were attributed to each chromo-
some based on the size of EcoRI restriction fragments (Figure S1).
To define the SSLP and the pLAM SNP (AT(T/C)AAA) sequences
flanking the D4Z4 repeat units, linear gel electrophoresis of
EcoRI-digested DNA was used to isolate each D4Z4-reduced allele.
The SSLP sequence was determined after PCR amplification using
specific oligonucleotides (forward primer 50-GGTGGAGTTCTGGT
TTCAGC-30 labeled with hexachlorofluorescein [HEX], reverse
primer 50-CCTGTGCTTCAGAGGCATTTG-30) as previously re-
ported.17,18 Analysis of the pLAM SNP was performed on PCR-
amplified DNA using specific oligonucleotides (forward primer
50-ACGCTGTCTAGGCAAACCTG-30, reverse primer 50-TGCAC
TCATCACACAAAAGATG-30). SSLP size differences and pLAM
sequences were analyzed using an ABI Prism 3130 Genetic
Analyzer.17,18Results
Presence of FSHD-Sized Alleles in the Healthy
Population
Previous smaller investigations of the Dutch population
suggested that 3% of healthy subjects had D4Z4 alleles of
35–38 kb in size, and one-third of these might present
a potentially pathogenic 4A allele.11,24 An additional
recent genetic criteria is that, in order to have FSHD, the
reduction of D4Z4 repeats must be associated with
a specific chromosomal background, 4A(159/161/168)
PAS, allowing the expression of the DUX4 gene.18
However, the frequency of compound heterozygotes in
patients with FSHD suggested that the frequency of
D4Z4-reduced 24–35 kb alleles associated with the
4A161PAS in the Italian population would be >1%.20
Because this prediction has crucial implications for clinical
practice, we searched for D4Z4-reduced alleles associated
with the 4A161PAS haplotype in 801 healthy individuals,
560 from Italy and 241 from Brazil. Figure 2 shows that
25 of these 801 subjects carry D4Z4 alleles ranging from
21 to 35 kb (4 to 8 D4Z4 units); 17 of these 25 alleles are
associated with 4qA (Figure 2, groups 1 and 2), and 11 carry
the 4A161PAS haplotype (Figure 2, group 1; Figures S2–S7).
Therefore, 3% (25 of 801) of normal controls carry D4Z4
alleles of reduced size, and ~1.3% (11) have the supposedly
pathogenic 4A161PAS haplotype. The age of all these
healthy carriers ranged between 40 and 78 years, an age
in which FSHD is considered to be fully penetrant. On
this basis, we conclude that the haplotype 4A161PAS has
the frequency of a common polymorphism and that it012
Figure 2. Molecular Haplotypes of 25 Healthy
Subjects from Italian and Brazilian Control
Populations
Haplotypes of 25 4q alleles with 4–8 D4Z4 repeats
identified in 801 normal healthy individuals
randomly selected from the general populations
of Italy and Brazil. We characterized the sequence
variants in the SSLP (colored rectangles), D4Z4
repeat number (triangles), distal variants A or B
(shaded boxes), and the pLAM PAS (unshaded
rectangles). The second and third columns
present the number of reduced D4Z4 alleles de-
tected (N), the provenance (p) of the subjects
(Ita for Italy and Bra for Brazil), and the preva-
lence of each haplotype among the 801 individ-
uals examined (%). The supposedly pathogenic
haplotype 4A161PAS is the most frequent and is
present in 1.3% of healthy controls.
Table 1. Distribution of 253 Unrelated FSHD Patients versus D4Z4
Repeat Units
Number of Unrelated FSHD Patients
D4Z4 Repeat Units De Novo Cases Familial Cases Percentage
1–3 5 22 10.7%
4–8 2 175 69.9%
9–10 0 19 7.5%
>11 0 30 11.8%may be permissive but is not sufficient to cause autosomal-
dominant disease.
Multiple Haplotypes Associated with FSHD
Our observation that in the general population 1.3% of
healthy subjects carry the FSHD ‘‘pathogenic’’ signature
4A161PAS, which enables the expression of DUX4, chal-
lenges the notion that FSHD is a fully-penetrant auto-
somal-dominant disorder caused by the reduction of
D4Z4 repeat number associated with 4A161PAS haplotype.
To test theDUX4 polyadenylation model more broadly, we
systematically studied the 4q35 haplotype of 253 probands
accrued through the Italian National Registry for FSHD
(Table S2). The D4Z4 repeat size was systematically studied
in all subjects. Table 1 shows that 204 of 253 probands
(80.6%) carry D4Z4 alleles with 1–8 units, 19 (7.5%) have
D4Z4 alleles with 9–10 repeats, and the remaining 30
(11.8%) show large D4Z4 alleles (R11 repeats) on both
copies of chromosome 4 (Table 1). We then analyzed the
223 FSHD patients with 10 or fewer D4Z4 repeats for the
presence of the 4A/B, PAS, and SSLP (see Figure 1). Only
127 FSHD probands carry the 4A161PAS haplotype associ-
ated with alleles having 1–8 D4Z4 repeats (group 1 in
Figure 3). Among the remaining probands, 52 have
reduced alleles associated with the 4A166PAS haplotype
previously considered to not be ‘‘permissive’’ for FSHD
disease (group 2 in Figure 3), 13 carry the 4A162PAS, 5
carry the 4A164PAS, 2 carry the 4A167PAS, 1 carries the
4A163PAS (groups 7–10 in Figure 3), and 3 bear reduced
D4Z4 alleles with the 4qB polymorphism, which lacksThe American Journal ofboth the pLAM region and the PAS (groups
3–4 in Figure 3). Examples of each group
are reported in Figures S8–S12. Collectively,
our data reveal that in our cohort of FSHD
probands the SSLP allelic variants associated
with D4Z4-reduced alleles differ from those
previously reported (compare groups 2–10
in Figure 3 with Figure 1).17,18 This geno-
typic difference is also supported by the
fact that we did not find the 4A168 ‘‘permis-sive’’ haplotype associated with FSHD in our population.
In contrast, haplotypes considered to not be ‘‘permissive’’
for FSHD disease were frequent. In particular, the
4A166PAS haplotype is present associated with almost
one-quarter (23.3%) of D4Z4-reduced alleles detected in
our FSHD probands. More importantly, 49 of 253 FSHD
probands (19%) carry alleles with more than 8 D4Z4
repeats, and only 127 (50.1%) carry D4Z4-reduced alleles
associated with the 4A161PAS, the expected molecular
signature for FSHD.
Discussion
The practice of medical genetics requires a clear, definite
evaluation of the significance of mutations and/or varia-
tions of DNA sequences for diagnosis to provide prognostic
information and genetic counseling. This is particularly
important for a progressive disease with unpredictableHuman Genetics 90, 628–635, April 6, 2012 631
Figure 3. Molecular Haplotypes of 223 Unrelated FSHD Patients
Overview of haplotypes of the D4Z4-reduced alleles (%10 repeats) on chromosome 4 found in 223 unrelated FSHD patients. Alleles are
separated into 1–3 (column 1), 4–8 (column 3), and 9–10 (column 5) D4Z4 repeat units. Within these columns, we group the observed
haplotypes based on the type of SSLP and PAS. N indicates the number of alleles found in each haplotype, and TOT(%) represents the
total number of alleles found and the prevalence of each haplotype. The 4A haplotypes not previously observed in FSHDpatients include
4A166 (group 2), 4A162 (group 7), 4A164 (group 8), 4A167 (group 9), and 4A163 (group 10), and the 4B haplotypes include 4B163 (group
3) and 4B166 (group 4). Frequencies of 4A161 (group 1, 63.7%) and 4A166 (group 2, 25.1%) are different than previously reported in
other normal populations. Chromosomes with 4qB haplotypes (groups 3–4) lack the pLAM and PAS.onset and a high variability of clinical expression, such as
FSHD.
The extensive use over the past 20 years of DNA anal-
ysis for studying Mendelian disorders has revealed many
complex mechanisms in addition to single mutant genes
that cause disease. Identical phenotypes may be produced
by mutations in different genes,25 the same mutation can
cause different phenotypes,26 and distinct mutations in
the same gene may result in different disorders that
segregate with diverse Mendelian or even multifactorial
patterns.27 In addition, the incomplete penetrance of
certain mutations argues for the importance of modifying
loci or epigenetic mechanisms influencing the clinical
expression in many Mendelian disorders.28 Thus, estab-
lishing the value of mutational events underlying genetic
diseases may be complex even when there are simple632 The American Journal of Human Genetics 90, 628–635, April 6, 2patterns of inheritance in diseases with a well-character-
ized pathologic course.
FSHD seems to fall in this complex pattern, even
though it is currently considered to be a fully penetrant
disease with a wide variability in clinical spectrum,
ranging from subjects with very mild muscle weakness
to wheelchair-bound patients.5,13 The molecular test
initially used for FSHD diagnosis was based on the obser-
vation that 95% of FSHD patients carry a reduction of
integral numbers of D4Z4 repeats at 4q35 with full pene-
trance.10 However, the wide use of this test revealed
several exceptions to the original model. Through the
years, the threshold size of D4Z4 alleles has been
increased from the original 28 kb7 (6 repeats) to 35 kb10
(8 repeats), with FSHD cases carrying D4Z4 alleles of 38–
41 kb (9–11 repeats), considered borderline alleles.22,29012
Additional genotype-phenotype studies led to the identifi-
cation of subjects carrying D4Z4-reduced alleles with no
sign of muscle weakness in FSHD families,14,15 as well as
of healthy unrelated subjects without family history of
FSHD.11,30 The present results from our systematic clinical
and molecular analysis of FSHD patients from the Italian
National Registry for FSHD, as well as a large number of
healthy controls, challenge the current model for FSHD
diagnosis.
Remarkably, our data establish as a general rule rather
than an exception that detection of a D4Z4-reduced
allele is not sufficient to diagnose FSHD. Although
the majority of FSHD patients (70%) carry D4Z4
alleles with 4–8 units, this size range is carried by 3% of
healthy subjects from the general population. Addition-
ally, there is little predictive value of the 4qA161PAS
haplotype in the absence of family history, because
1.3% of healthy subjects carry this haplotype, which
therefore has the frequency of a common polymorphism
(Figure 1) rather than a rare mutation. Finally, 49 of 253
probands (19%) do not carry D4Z4 alleles with 1–8
repeats, and only 50% of the probands carry the 4A161
permissive haplotype.
In summary, our study indicates that a profound
rethinking of the genetic disease mechanism and modes
of inheritance of FSHD are now required and that entirely
newmodels and approaches are needed. Our results do not
exclude an important pathogenic role for DUX4 or other
candidate factors but do establish a complex mechanism
beyond current understanding. Indeed, our data point
at the possibility that in the heterozygous state a D4Z4
reductionmight produce a subclinical sensitized condition
that requires other epigenetic mechanisms or a contrib-
uting factor to cause overt myopathy. In some rare cases,
that could be by becoming homozygous20 and doubling
the dose of a dominant factor such as DUX4. In others, it
might be by the simultaneous heterozygosity for a different
and recessive myopathy, as suggested by many reports
in which the FSHD contractions are found in association
with a second molecular defect.31–44 This possibility is
also consistent with previous reports of expression
changes of candidate proteins such as CRYM that were
associated with FSHD in some families but that were
unchanged when other families were examined. Finally,
it is also plausible that drugs or toxic agents might
contribute to the disease onset and clinical variability.
This would explain the observation of discordant mono-
zygotic twins carrying the FSHD reduction.45,46 It is hoped
that broadening the scope of investigations, including
next-generation deep sequencing in particular in families
with asymptomatic and clinically affected members
carrying the same FSHD allele, may finally lead to an
understanding of the molecular pathogenesis of this
complex disease. These findings have important clinical
implications for genetic counseling of patients and fami-
lies with FSHD, with particular regard to the interpretation
of data in prenatal diagnosis.The AmSupplemental Data
Supplemental Data include twelve figures and two tables and can
be found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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